The team
Christopher Potts, B.S., J.D., Chief Executive Officer
Christopher Potts, B.S., J.D., Chief Executive Officer
Christopher Potts, B.S., J.D., Chief Executive Officer
From a childhood on the farm to having led multiple $100+ million deals in cell therapy, Chris's vision and leadership brings products to market. Most recently with Legend Biotech, Chris has spent well over a decade developing teams and leading organizations to capture innovation and create commercial value in biotech.
Nicholas Ostrout, Ph.D., Chief Business Advisor
Christopher Potts, B.S., J.D., Chief Executive Officer
Christopher Potts, B.S., J.D., Chief Executive Officer
A breadth of experience over two decades at Lonza, Miltenyi, and as a founder of biotech startups, Nick is set to drive value capture with Monarch Therapeutics. Nick employs an innovative approach to advancing therapies and driving business development. Nick continues to lead progress in cell therapy development, manufacturing, and licensing at Charles River Labs.
Matt Hewitt, Ph.D., Scientific Consultant
Christopher Potts, B.S., J.D., Chief Executive Officer
Matt Hewitt, Ph.D., Scientific Consultant
A true thought-leader in cell therapy, Matt is now leveraging his expertise to bring new ideas to Monarch Therapeutics. As an industry leader, Matt is dedicated to driving the development and growth of novel personalized treatments. Matt has cultivated his skills while developing cell therapies with UPenn, Bellicum, Lonza, and Charles River Labs.
adAptive platform
Modular, Mix-and-Match Approach
Monarch Therapeutics harnesses the immune system to provide constructs that are universal across indications—leveraging platform technology allows for speed, efficiency, and clinical outcomes. Universality allows us to mix-and-match for each situation.
Multi-Modal and Multi-Targeting
Monarch Therapeutics’ adaptors are flexible and multi-modal including novel small molecule adaptors as well as antibody and protein adaptor strategies. This flexibility allows multiple antigen targeting and unlocks the dosing, clearance, and manufacturing advantages of all molecules.
Scientific PUblications
mSA2 Affinity-Enhanced Biotin-Binding CAR T Cells for Universal Tumor Targeting
Dr. Jason Lohmueller's seminal publication in OncoImmunology on his universal construct anti-tag CAR.
Jason J. Lohmueller, James D. Ham, Michael Kvorjak & Olivera J. Finn (2018) mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting, OncoImmunology, 7:1, DOI: 10.1080/2162402X.2017.1368604
Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targetin
Nature Communications article describing additional universal CAR constructs and adaptors.
Ruffo, E., Butchy, A.A., Tivon, Y. et al. Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting. Nat Commun 14, 2463 (2023). https://doi.org/10.1038/s41467-023-37863-5
Conditional Control of Universal CAR T Cells by Cleavable OFF-Switch Adaptors
Conditional Control of Universal CAR T Cells by Cleavable OFF-Switch Adaptors - PMC (nih.gov)
American Chemical Society publication of conditional control strategies.
Kvorjak M, Ruffo E, Tivon Y, So V, Parikh A, Deiters A, Lohmueller J. Conditional Control of Universal CAR T Cells by Cleavable OFF-Switch Adaptors. ACS Synth Biol. 2023 Oct 20;12(10):2996-3007. doi: 10.1021/acssynbio.3c00320. Epub 2023 Oct 4. PMID: 37791909; PMCID: PMC10594876.